Associated Papers
Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.
Hayes TK et al.
Nature Communications, 2024
Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M.
Wang LS et al.
Anti-cancer Drugs, 2023
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
Multiple mutations in the EGFR gene in lung cancer: a systematic review.
Castañeda-González JP et al.
Translational Lung Cancer Research, 2022
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
Mu Y et al.
Journal of Cancer Research and Clinical Oncology, 2020
Mutational Portrait of Lung Adenocarcinoma in Brazilian Patients: Past, Present, and Future of Molecular Profiling in the Clinic.
Freitas HC et al.
Frontiers in Oncology, 2020
Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing.
Kohsaka S et al.
Future Oncology (london, England), 2019
Evolution of oncogenic signatures of mutation hotspots in tyrosine kinases supports the atavistic hypothesis of cancer.
Chen W et al.
Scientific Reports, 2018
A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.
Kohsaka S et al.
Science Translational Medicine, 2017
Structural Stability and Flexibility Direct the Selection of Activating Mutations in Epidermal Growth Factor Receptor Kinase.
Paladino A et al.
Journal of Chemical Information and Modeling, 2015
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.
Tsao AS et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2013
DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.
Yeh P et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Liu Y et al.
International Journal of Clinical and Experimental Pathology, 2013
Routine EGFR and KRAS Mutation analysis using COLD-PCR in non-small cell lung cancer.
Pennycuick A et al.
International Journal of Clinical Practice, 2012
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Wu JY et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
The energy landscape analysis of cancer mutations in protein kinases.
Dixit A et al.
Plos One, 2011
Co-conserved features associated with cis regulation of ErbB tyrosine kinases.
Mirza A et al.
Plos One, 2010
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study.
Giaccone G et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2006